Shares of Relief Therapeutics’ (SIX: RLF) closed the week 1,341% higher after its RLF-100 COVID-19 treatment showed an early potential in the second testing phase.
The chairman of the firm, Raghuram Selvaraju, believes that there is a “60%-70%” chance to get approval for the drug.
“From an efficacy standpoint we need more data. I would say the probability at the moment stands at 60 to 70% that we will get the drug approved,” Selvaraju told Swiss newspaper The Market.
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
“The active pharmaceutical ingredient of aviptadil has been used for a lot of years in different indications. From a safety standpoint we are quite optimistic,” he added.
Relief holds a patent for Europe and the United States. It partnered with NeuroRx to run multicentre clinical trials. RLF-100 is targeting patients who are severely ill with COVID-19 infections, helping them to survive.
“I do not anticipate that we would need ten to 12 months for approval,” he concluded.
Relief Therapeutics’ share price closed 1,341% higher after trading over 2,100% in the green on Thursday.
